Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vivus Inc VVUSQ

Healthcare Biotechnology
VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic... see more

Recent & Breaking News (OTCPK:VVUSQ)

VIVUS Completes Solicitation for In-Court Reorganization Plan to Become a Wholly Owned Subsidiary of IEH Biopharma LLC

GlobeNewswire July 7, 2020

VIVUS Announces Updated Agreement with Icahn Enterprises Holdings L.P.

GlobeNewswire June 2, 2020

VIVUS Reports First Quarter 2020 Financial Results

GlobeNewswire May 6, 2020

VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Wednesday, May 6, 2020

GlobeNewswire May 1, 2020

VIVUS Announces Agreement with IEH Biopharma LLC Granting the Company a 30-Day Grace Period to Restructure its Corporate Debt

GlobeNewswire May 1, 2020

VIVUS Announces Closing of $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

GlobeNewswire April 3, 2020

VitalTech Partners with VIVUS Pharmaceuticals to Accelerate Launch of Telehealth and Remote Patient Monitoring Modules

PR Newswire April 3, 2020

VIVUS Announces $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

GlobeNewswire April 1, 2020

VIVUS Accelerates the Launch of Telemedicine and Remote Monitoring Modules to Facilitate Effective Patient Care During "Social Distancing"

GlobeNewswire March 31, 2020

VIVUS Reports Fourth Quarter and Full Year 2019 Financial Results

GlobeNewswire March 3, 2020

VIVUS Completes Enrollment in Phase 4 Safety and Efficacy Study of Qsymia® in Adolescents

GlobeNewswire March 2, 2020

VIVUS Announces Commercial Launch of Qsymia® in the Republic of Korea Establishing New Royalty Revenue Stream

GlobeNewswire February 19, 2020

VIVUS to Host Fourth Quarter Business Update and Financial Results Conference Call on Tuesday, March 3, 2020

GlobeNewswire February 18, 2020

VIVUS Receives U.S. Food and Drug Administration Approval for Improved Formulation of PANCREAZE® with a 36-Month Shelf Life

GlobeNewswire February 5, 2020

New Data Further Demonstrate Effectiveness of VIVUS' Qsymia as a Weight Management Tool

GlobeNewswire January 7, 2020

VIVUS to Present at Biotech Showcase on January 13, 2020

GlobeNewswire January 2, 2020

VIVUS Adopts Stockholder Rights Plan

GlobeNewswire December 31, 2019

VIVUS Announces New Data Supporting the Safety and Efficacy of Qsymia® in Adolescents with Obesity

GlobeNewswire December 18, 2019

VIVUS to Present at Piper Jaffray 31st Annual Healthcare Conference on December 3, 2019

GlobeNewswire November 25, 2019

New Clinical Data Demonstrate VIVUS' Qsymia® is Effective at Reducing Binge Eating in Patients with Binge-Eating Disorder or Bulimia Nervosa

GlobeNewswire November 20, 2019